Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation
$PAHC
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $22.00 | Neutral | JP Morgan |
| 12/7/2023 | $9.00 | Underperform | Exane BNP Paribas |
| 12/21/2022 | $18.00 | Buy | ROTH Capital |
| 7/25/2022 | $22.00 | Equal Weight → Underweight | Barclays |
| 1/10/2022 | $23.00 | Underweight → Equal-Weight | Barclays |
| 11/18/2021 | $23.00 | Equal-Weight | Morgan Stanley |
| 8/5/2021 | $25.00 | Neutral | Credit Suisse |
| 7/7/2021 | $23.00 | Equal-Weight → Underweight | Barclays |
Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition for better lives and a more sustainable world. "Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro's species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world," said Jack C
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To acc
Phibro Animal Health Corporation (NASDAQ:PAHC) announced today it will participate in the Morgan Stanley Annual Global Healthcare Conference. Chief Financial Officer, Glenn David along with Chief Operating Officer, Larry Miller will address financial analysts and investors on Thursday, September 5, 2024, at 1:05 PM ET at the New York Marriott Marquis. The live audio presentation will be available on the Phibro Animal Health Corporation Investor Relations Website at https://investors.pahc.com. A replay of the session will be available and archived on the company's website. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal h
Damian Finio to Succeed Javier Daly as Chief Financial Officer TRENTON, N.J., Sept. 6, 2023 /PRNewswire/ -- TerraCycle Inc., the international leader in innovative sustainability solutions, today announced Damian Finio will join the company's global leadership team as Chief Financial Officer, effective October 2. Finio most recently served as Chief Financial Officer of Phibro Animal Health Corporation (NASDAQ:PAHC) and joins TerraCycle with more than 30 years of financial management experience, primarily in the life sciences industry having spent nearly half of his career at
The Board of Directors of Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the appointment of Alejandro Bernal, DVM, MS, MBA, as a Class III director of the Company, effective immediately. Mr. Bernal will be an independent director. His appointment fills a current vacancy and increases Board membership to nine directors, 6 of whom are independent directors. Mr. Bernal recently became Chief Executive Officer of PetDx® – The Liquid Biopsy Company for Pets™, a company based in San Diego, CA, and focused on early detection of cancer using Next Generation Sequencing (NGS) technology. Prior to joining PetDx, Mr. Bernal was the President for Mars Veterinary Health International and
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its first quarter financial results on Wednesday, November 6, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, November 7, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of the live event. To acc
Phibro Animal Health Corporation (NASDAQ:PAHC) ("Phibro" or the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2024 and provided its financial guidance for the year ending June 30, 2025. Highlights for the three months ended June 30, 2024 (compared to the three months ended June 30, 2023) Net sales of $273.2 million, an increase of $18.1 million, or 7% Net income of $0.8 million, a decrease of $10.7 million Diluted earnings per share of $0.02, a decrease of $0.26 Adjusted EBITDA of $33.4 million, an increase of $1.1 million, or 3% Adjusted net income of $16.7 million, an increase of $1.5 million, or 10% Adjusted diluted
Phibro Animal Health Corporation (NASDAQ:PAHC) expects to announce its fourth quarter and fiscal year 2024 financial results on Wednesday, August 28, 2024, after the market closes. Phibro management will host a conference call and webcast on Thursday, August 29, 2024, at 9:00 AM Eastern Time. Interested parties are invited to listen to the conference call and view the presentation slides by visiting https://investors.pahc.com. The discussion will also be available by dialing +1 (888) 330-2022 in the U.S. and Canada, or +1 (365) 977-0051 for international callers. Provide the conference ID 3927884. A replay of the webcast will be available approximately two hours after the conclusion of
JP Morgan initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $22.00
Exane BNP Paribas initiated coverage of Phibro Animal Health with a rating of Underperform and set a new price target of $9.00
ROTH Capital initiated coverage of Phibro Animal Health with a rating of Buy and set a new price target of $18.00
SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
SC 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
SCHEDULE 13G - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)
DEFA14A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
3 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)
Barclays analyst Balaji Prasad maintains Phibro Animal Health (NASDAQ:PAHC) with a Underweight and raises the price target from $10 to $13.
Phibro Animal Health (NASDAQ:PAHC) reported quarterly earnings of $0.31 per share which beat the analyst consensus estimate of $0.29 by 6.9 percent. This is a 6.9 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $263.200 million which beat the analyst consensus estimate of $254.825 million by 3.29 percent. This is a 7.12 percent increase over sales of $245.700 million the same period last year.